The goal of our study is to establish mouse models for fast in vivo efficacy studies of biologics, such as CAR-T and therapeutic antibody candidates.B-NDG mice (NOD-Prkdcscid/l2rgm/Bcgen) were independently developed by Biocytogen by knocking out the lL2rg genein the NOD-scid mouse back ground. B-NDG are one of the most severely immunodeficient mice, completely lacking mature T, B and NK cells and were def icient in cytokine signaling. We have established more than 24 CDX models using B-NDG mice, including human solid tumor and bloodtumor cellines,such as bladder carcinoma, breast cancer, colon carcinoma, colorectal adenocarcinoma, glioblastoma, liver cancer, lung carcinoma,and various leuke mia and lymphoma cell lines. We have previously demonstrated that B-NDG mice inoculated with humantumor cells can be usedforCAR-T therapy eval uation.
